With philanthropic support, Cedars-Sinai has developed a novel therapy aimed at preventing and treating organ rejection. The new drug has been given fast-track approval by the Food and Drug Administration and would make otherwise incompatible transplants possible.
Cedars-Sinai surgeons have been performing transplantations since 1966, while collaborating with scientists to pioneer techniques that improve matchmaking—including ways to unite incompatible blood types and prevent organ rejection.
A common tool for preventing bedsores also can predict recovery rates for liver transplant recipients, according to Cedars-Sinai investigators. “We’ve made advances in liver transplantation so that people can live longer than ever. However, we have had no good way Read On
It’s well-known that the number of kidney donors falls far short of the number of people in need of a kidney transplant. What’s less known is an extraordinary pay-it-forward solution to the shortage that involves a chain of Good Samaritans and makes it possible for more men and women on the waitlist to receive a new organ.
While most patients recover fully from open-heart surgery, some suffer long-term effects from the stress caused by the operation. Cedars-Sinai scientists are collecting data — and damaged cells — from heart transplant patients to improve recovery.
Millions of lives have been saved since the first organ transplantation in 1954. Today’s leading-edge technology brings new promise but barriers remain. We asked 14 experts for their big ideas on how to improve the dynamic field.